Zimmer Biomet (ZBH)
(Delayed Data from NYSE)
$106.42 USD
+0.08 (0.08%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $106.39 -0.03 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$106.42 USD
+0.08 (0.08%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $106.39 -0.03 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum C VGM
Zacks News
Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.
Zimmer Biomet (ZBH) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 1.28% and 2.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Envista (NVST) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Envista (NVST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Zimmer Biomet (ZBH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zimmer Biomet (ZBH) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet (ZBH) might have faced an upheaval in business, thanks to the global inflationary situation in terms of mounting labor and raw material costs.
Zimmer Biomet (ZBH) to Offer New Shoulder Replacement System
by Zacks Equity Research
Zimmer Biomet (ZBH) gets FDA nod for the Identity Shoulder System to help surgeons perform anatomic, reverse and revision shoulder replacement with precision.
Zimmer (ZBH) Surges 4.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Zimmer (ZBH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zimmer Biomet (ZBH) Procedure Recovery Strong, Margin Woe Stays
by Zacks Equity Research
Zimmer Biomet's (ZBH) recently completed spin-off of the non-core dental and spine business is expected to prove strategic.
Zimmer Biomet (ZBH) Signs Co-Marketing Agreement for HipInsight
by Zacks Equity Research
Zimmer Biomet's (ZBH) HipInsight is a mixed reality-based visualization tool that will aid surgeons in precise implant placement and alignment during total hip replacement.
Zimmer (ZBH) Down 8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
4 Stocks to Watch Amid Recovering Medical Products Industry
by Indrajit Bandyopadhyay
Despite the COVID-induced challenges, rising demand for IVD coupled with dependence on AI & Robotics should lend support to the Zacks Medical-Products industry. ZBH, BIO, LNTH and HAE are well-poised to gain from the favorable factors.
Accuray (ARAY) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Despite solid Product revenues, Accuray (ARAY) reports an overall soft Q4 performance.
Alcon (ALC) Q2 Earnings Surpass Estimates, Guidance Lowered
by Zacks Equity Research
Alcon's (ALC) robust innovation pipeline is delivering solid results as evidenced by the successful launch of new ATIOL roles and SiHy contact lenses.
Masimo's (MASI) Q2 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Masimo's (MASI) robust product shipments and strength in its healthcare business drive its Q2 sales.
Avanos (AVNS) Q2 Earnings Top Estimates, FY22 View Lowered
by Zacks Equity Research
Avanos's (AVNS) second-quarter 2022 results reflect strength in the Pain Management segment.
Zimmer Biomet (ZBH) Sees Business Recovery, Global Growth
by Zacks Equity Research
Zimmer Biomet (ZBH) revenues ride on continued execution along with strong COVID recovery across most markets.
Lantheus Holdings, Inc. (LNTH) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Lantheus Holdings (LNTH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
OPKO Health (OPK) Stock Gains 2.1% Despite Q2 Earnings Miss
by Zacks Equity Research
OPKO Health's (OPK) second-quarter results benefit from continued strength in its Pharmaceuticals segment.
Inogen (INGN) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Inogen's (INGN) second-quarter results benefit from higher revenues in its international business-to-business sales channel.
Allscripts (MDRX) Q2 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Allscripts' (MDRX) robust Q2 results demonstrate strength in both segments.
ZBH vs. LMAT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ZBH vs. LMAT: Which Stock Is the Better Value Option?
Zimmer Biomet (ZBH) Q2 Earnings Top Estimates, 2022 View Up
by Zacks Equity Research
The contraction in Zimmer Biomet's (ZBH) gross margin is concerning.
Zimmer Biomet (ZBH) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 11.66% and 3.31%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad Laboratories (BIO) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 37.40% and 3.94%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: NuVasive (NUVA) Q2 Earnings Expected to Decline
by Zacks Equity Research
NuVasive (NUVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Zimmer Biomet (ZBH) Q2 Earnings Expected to Decline
by Zacks Equity Research
Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.